Trial Profile

A clinical phase IIa study of Sevuparin in patients with anemia of chronic kidney disease

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 21 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Jul 2025 According to Modus Therapeutics media release, the completion of Part 1 of the Phase IIa study on schedule aligns with the Company's financing strategy for Part 2. The Board on 26 June resolved on a fully secured rights issue of approximately SEK 28.3 million-subject to approval at an extraordinary general meeting on 29 July 2025-to fund the next part of the study.
08 Jul 2025 According to Modus Therapeutics media release, the results will underpin the planned protocol amendment with dose recommendations to the second part of the study.
08 Jul 2025 According to Modus Therapeutics media release, the company intends to initiate Part 2 in Q4 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com